What is it about?
Patients with renal diseases present low levels of vitamin D. Some of them are treated with analogs of vitamin D. We described here the mechanisms involved in the beneficial effects of these drugs and a potential biomarker to monitor the response to vitamin D treatment.
Featured Image
Read the Original
This page is a summary of: TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease, Journal of the American Society of Nephrology, July 2020, American Society of Nephrology,
DOI: 10.1681/asn.2019111206.
You can read the full text:
Contributors
The following have contributed to this page
